EW - Edwards Lifesciences Corporation
| Previous Close | 215.21 |
| Open | 218.00 |
| Bid | 208.00 x 1200 |
| Ask | 220.95 x 800 |
| Day's Range | 217.01 - 220.48 |
| 52 Week Range | 136.44 - 220.48 |
| Volume | 1,082,665 |
| Avg. Volume | 1,283,523 |
| Market Cap | 45.616B |
| Beta (3Y Monthly) | 0.92 |
| PE Ratio (TTM) | 64.27 |
| EPS (TTM) | 3.41 |
| Earnings Date | Oct 21, 2019 - Oct 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 213.45 |
- Reuters
UPDATE 1-Edwards Lifesciences, Medtronic heart valves win U.S. approval for expanded use
Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the U.S. FDA said on Friday. The Food and Drug Administration approved two of Edwards' transcatheter heart valve systems called Sapien 3 And Sapien 3 Ultra as well as Medtronic's Evolut Transcatheter Aortic Valve Replacement (TAVR)system.
- Investor's Business Daily
Medtech Stock Hits Record High On TAVR Nod For Healthier Patients
Shares of Medtronic and Edwards Lifesciences jumped Friday after the Food and Drug Administration approved their TAVR heart-valve replacement systems for healthier and younger patients.
- Investor's Business Daily
Edwards Lifesciences' Medical Breakthrough Heats Up This Frost Mutual Fund
Frost Equity Growth Fund invests in secular, consistent and cyclical growth stocks. Here's why most of the fund's bets are on secular growers.
- PR Newswire
Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
IRVINE, Calif., Aug. 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3 and SAPIEN 3 Ultra transcatheter heart valve systems to the treatment of severe, symptomatic aortic stenosis (AS) patients who are determined to be at low risk of open-heart surgery. "The PARTNER 3 Trial demonstrated that low-risk patients treated with the SAPIEN 3 TAVR experienced extraordinary outcomes with 1.0 percent rates of death or disabling stroke at one year, a short length of stay and 96 percent discharged to home or self-care. SAPIEN 3 is the only valve to achieve superiority over surgery based on the prespecified primary endpoint," said Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Medical Center and professor of medicine at the Columbia University College of Physicians and Surgeons.
- Zacks
HMS Holdings (HMSY) Soars to 52-Week High, Time to Cash Out?
HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
Here is Why Growth Investors Should Buy Edwards Lifesciences (EW) Now
Edwards Lifesciences (EW) could produce exceptional returns because of its solid growth attributes.
- Simply Wall St.
An Examination Of Edwards Lifesciences Corporation (NYSE:EW)
I've been keeping an eye on Edwards Lifesciences Corporation (NYSE:EW) because I'm attracted to its fundamentals...
- Thomson Reuters StreetEvents
Edited Transcript of EW earnings conference call or presentation 23-Jul-19 9:00pm GMT
Q2 2019 Edwards Lifesciences Corp Earnings Call
- Simply Wall St.
A Closer Look At Edwards Lifesciences Corporation's (NYSE:EW) Impressive ROE
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Motley Fool
10 Biggest Medical Device Stocks
Market caps for these medical device stocks are big. Most of them have been big winners, too.
- Zacks
Edwards Lifesciences Corporation (EW) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Edwards Lifesciences Corporation (EW).
- Benzinga
The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
- Motley Fool
Why Edwards Lifesciences Stock Is Jumping Today
The company's great Q2 results and increase to its full-year 2019 outlook are making investors happy.
- Market Realist
TAVR Is a Key Growth Driver for Edwards Lifesciences
In the second quarter, Edwards Lifesciences (EW) has guided for TAVR sales of $2.5 billion to $2.7 billion in fiscal 2019.
- Market Realist
Edwards Lifesciences Stock Rose on Earnings Beat
Yesterday, Edwards Lifesciences (EW) reported its second-quarter earnings results after the close of the regular trading session.
- Zacks
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.
- Benzinga
The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...
- Motley Fool
Edwards Lifesciences Boosts Outlook After Posting Strong Q2 Earnings
The artificial-heart valve maker delivered another impressive performance in Q2.
Motley FoolEdwards Lifesciences Corp (EW) Q2 2019 Earnings Call Transcript
EW earnings call for the period ending June 30, 2019.
- Zacks
Edwards Lifesciences (EW) Q2 Earnings and Revenues Top Estimates
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.76% and 4.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Investor's Business Daily
How This Big Cap 20 Stock Is Expanding Its Biggest Moneymaker — Again
Edwards Lifesciences reported income of $1.38 per share and $1.09 billion in sales for the quarter ended June 30. A year ago, Edwards earnings were $1.24 a share on $943.7 million in sales.
- PR Newswire
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif. , July 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...
- ACCESSWIRE
Edwards Lifesciences Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 23, 2019 / Edwards Lifesciences Corp. (NYSE: EW ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 23, 2019 at 5:00 PM ...
